HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance mechanis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alison E. Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J. Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B. Solit, Elisa de Stanchina, Jorge Reis-Filho, Neal Rosen, Joaquín Arribas, Pedram Razavi, Sarat Chandarlapaty
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/0069fe3f63d440449928bce36543115c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0069fe3f63d440449928bce36543115c
record_format	dspace
spelling	oai:doaj.org-article:0069fe3f63d440449928bce36543115c2021-11-21T12:34:23ZHER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway10.1038/s41467-021-27093-y2041-1723https://doaj.org/article/0069fe3f63d440449928bce36543115c2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-27093-yhttps://doaj.org/toc/2041-1723Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance mechanism.Alison E. SmithEmanuela FerraroAnton SafonovCristina Bernado MoralesEnrique J. Arenas LahuertaQing LiAmanda KulickDara RossDavid B. SolitElisa de StanchinaJorge Reis-FilhoNeal RosenJoaquín ArribasPedram RazaviSarat ChandarlapatyNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Alison E. Smith Emanuela Ferraro Anton Safonov Cristina Bernado Morales Enrique J. Arenas Lahuerta Qing Li Amanda Kulick Dara Ross David B. Solit Elisa de Stanchina Jorge Reis-Filho Neal Rosen Joaquín Arribas Pedram Razavi Sarat Chandarlapaty HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
description	Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose genetic activation of MAPK as a resistance mechanism.
format	article
author	Alison E. Smith Emanuela Ferraro Anton Safonov Cristina Bernado Morales Enrique J. Arenas Lahuerta Qing Li Amanda Kulick Dara Ross David B. Solit Elisa de Stanchina Jorge Reis-Filho Neal Rosen Joaquín Arribas Pedram Razavi Sarat Chandarlapaty
author_facet	Alison E. Smith Emanuela Ferraro Anton Safonov Cristina Bernado Morales Enrique J. Arenas Lahuerta Qing Li Amanda Kulick Dara Ross David B. Solit Elisa de Stanchina Jorge Reis-Filho Neal Rosen Joaquín Arribas Pedram Razavi Sarat Chandarlapaty
author_sort	Alison E. Smith
title	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
title_short	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
title_full	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
title_fullStr	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
title_full_unstemmed	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
title_sort	her2 + breast cancers evade anti-her2 therapy via a switch in driver pathway
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0069fe3f63d440449928bce36543115c
work_keys_str_mv	AT alisonesmith her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT emanuelaferraro her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT antonsafonov her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT cristinabernadomorales her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT enriquejarenaslahuerta her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT qingli her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT amandakulick her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT daraross her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT davidbsolit her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT elisadestanchina her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT jorgereisfilho her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT nealrosen her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT joaquinarribas her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT pedramrazavi her2breastcancersevadeantiher2therapyviaaswitchindriverpathway AT saratchandarlapaty her2breastcancersevadeantiher2therapyviaaswitchindriverpathway
_version_	1718418864810754048

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Ejemplares similares